Immunologically, we further found that TRIM36, an E3 ubiquitin-protein ligase, was upregulated in a dose-dependent manner by BET Bromodomain inhibition combined with IFN-γ; increased TRIM36 expression has been correlated with inhibition of prostate cancer proliferation and cell-cycle progression through inhibition of the MAPK/ERK pathway [46]. Here, UBE2E3 is linked to prostate carcinoma.